Work

Eligibility criteria for clinical trials in AL amyloidosis result in exclusion of nearly half of real‐world patients

Year: 2026

Type: article

Source: HemaSphere

DOI: 10.1002/hem3.70320

Authors: Claudia Bellofiore, Marco Basset, Mario Nuvolone, Martina Nanci, Giuseppe D. Sanna, Valeria A. Di Simone, Alessandro Fogliani, Monica Di Cecca, Roberta Mussinelli, Andrea Foli, Matin Ghazi Esfahani, Mohammadjavad Sadrzadeh, Stefano Perlini, Leonardo De Luca, Solène Clavreul, Giampaolo Merlini, Giovanni Palladini, Paolo Milani

Institutions: University of Pavia, Policlinico San Matteo Fondazione, University of Sassari, Azienda Ospedaliero Universitaria di Sassari, Università Campus Bio-Medico, Campus Bio Medico University Hospital

Language: English

Topic: Amyloidosis: Diagnosis, Treatment, Outcomes

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,480

Funders: Cancer Research UK, European Commission, Fondazione Cariplo, Ministero della Salute, Associazione Italiana per la Ricerca sul Cancro

Awards: G2076520454, G2327242446, G2498377081, G2559588348, G657228599, G832744076

OpenAlex ID: W7129041537

FWCI: 1.828

Cites: 20

Cited by: 1

Related to: